Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NYSE:OKLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$54.65+0.2%$54.50$37.28▼$57.35$4.50B-0.41.86 million shs15.31 million shsOKLOOklo$60.93+6.0%$63.68$44.88▼$193.84$10.60B1.112.14 million shs5.12 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics0.00%0.00%0.00%0.00%-1.74%OKLOOklo0.00%-1.43%-7.81%-3.97%-9.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$54.65+0.2%$54.50$37.28▼$57.35$4.50B-0.41.86 million shs15.31 million shsOKLOOklo$60.93+6.0%$63.68$44.88▼$193.84$10.60B1.112.14 million shs5.12 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics0.00%0.00%0.00%0.00%-1.74%OKLOOklo0.00%-1.43%-7.81%-3.97%-9.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 2.00Hold$60.009.79% UpsideOKLOOklo 2.57Moderate Buy$82.7835.85% UpsideCurrent Analyst Ratings BreakdownLatest AKRO and OKLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026OKLOOklo UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$60.00 ➝ $55.005/26/2026OKLOOklo WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$110.005/22/2026OKLOOklo Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$80.005/22/2026OKLOOklo Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$80.005/19/2026OKLOOklo Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform5/14/2026OKLOOklo CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$73.50 ➝ $76.005/13/2026OKLOOklo Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026OKLOOklo WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$110.005/13/2026OKLOOklo Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$122.005/11/2026OKLOOklo JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$83.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AOKLOOkloN/AN/AN/AN/A$9.45 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$1.94N/AN/AN/AN/A-15.86%-14.78%N/AOKLOOklo-$105.66M-$0.84N/AN/AN/AN/A-8.57%-8.30%8/10/2026 (Estimated)Latest AKRO and OKLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026OKLOOklo-$0.20-$0.19+$0.01-$0.19N/AN/A3/17/2026Q4 2025OKLOOklo-$0.17-$0.27-$0.10-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AOKLOOkloN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero TherapeuticsN/A15.8415.83OKLOOkloN/A59.9359.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AOKLOOklo85.03%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%OKLOOklo18.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3082.32 million76.50 millionOptionableOKLOOklo78173.99 million141.11 millionOptionableAKRO and OKLO HeadlinesRecent News About These CompaniesWe See 66% Upside in Oklo as Pre-Revenue Nuclear Execution Risk Eases1 hour ago | 247wallst.comDown Around 70% From Its High, Is Now the Time to Buy Oklo Stock?1 hour ago | fool.comWe See 66% Upside in Oklo as Pre-Revenue Nuclear Execution Risk Eases2 hours ago | 247wallst.comNuclear Companies Turn to M&A to Secure Supply Chains4 hours ago | etftrends.comEOKLO Stock Is Bouncing Back: Bulls Are Talking About $100 Again After This DOE MilestoneJune 15 at 6:19 AM | stocktwits.comSBest Nuclear Stocks To Watch Today - June 14thJune 15 at 4:37 AM | americanbankingnews.comClear Street Group Inc. Has $60.43 Million Holdings in Oklo Inc. $OKLOJune 14 at 5:13 AM | marketbeat.comOklo (OKLO) Acquires ARMEC to Strengthen Vertically Integrated Nuclear ManufacturingJune 13 at 3:11 PM | insidermonkey.comOklo (OKLO) Acquires ARMEC to Strengthen Vertically Integrated Nuclear ManufacturingJune 13 at 3:02 PM | finance.yahoo.comVan ECK Associates Corp Acquires 481,288 Shares of Oklo Inc. $OKLOJune 13 at 7:01 AM | marketbeat.comHITE Hedge Asset Management LLC Has $7.44 Million Position in Oklo Inc. $OKLOJune 13 at 4:28 AM | marketbeat.comPromising Nuclear Stocks To Consider - June 10thJune 13 at 4:07 AM | americanbankingnews.comOklo clears regulatory hurdle for advanced Aurora reactor at Idaho National LaboratoryJune 12 at 6:56 PM | seekingalpha.comThe 127-Gigawatt Problem: Why AI Needs Its Own Power...June 12 at 11:20 AM | marketbeat.comOklo Strengthens Aurora-INL Path With DOE's PDSA ClearanceJune 12 at 9:06 AM | zacks.comPromising Nuclear Stocks To Follow Today - June 9thJune 12 at 5:19 AM | americanbankingnews.comDoes Oklo’s (OKLO) DOE Safety Milestone Quietly Redefine Its Path From Pilot To Fleet?June 11, 2026 | finance.yahoo.comWhy Oklo Stock Powered Higher TodayJune 11, 2026 | fool.comOklo (NYSE:OKLO) Trading 6.8% Higher - Still a Buy?June 11, 2026 | marketbeat.comDOE approval milestone for Oklo reactorJune 11, 2026 | world-nuclear-news.orgWOklo Stock Rises. Can Regulatory Progress Offset the Nuclear Start-Up’s Slump?June 11, 2026 | barrons.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026The 127-Gigawatt Problem: Why AI Needs Its Own PowerBy Jeffrey Neal Johnson | June 12, 2026AKRO and OKLO Company DescriptionsAkero Therapeutics NASDAQ:AKROAkero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Oklo NYSE:OKLO$60.93 +3.44 (+5.99%) As of 12:54 PM Eastern This is a fair market value price provided by Massive. Learn more.Oklo Inc. designs and develops fission power plants to provide reliable and commercial-scale energy to customers in the United States. It also provides used nuclear fuel recycling services. The company was founded in 2013 and is based in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
